← Xilio Therapeutics, Inc. (XLO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Xilio Therapeutics, Inc. (XLO)
Pharmaceutical Preparations · market cap $59M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Xilio Therapeutics (XLO) is a small-cap clinical-stage biotech with a $52M market cap and 64 employees, running three Phase 2 programs (XTX202, vilastobart/XTX101, XTX301) all targeting advanced solid tumors. The company holds $150.3M in cash against a 20.2-month runway, implying a meaningful net cash cushion relative to its current market capitalization. No recent clinical readouts have been reported, with the next scheduled event being an August 2026 earnings release.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| XTX202 | Phase 2 | Advanced Solid Tumor |
| vilastobart (XTX101) | Phase 2 | Advanced Solid Tumor |
| XTX301 | Phase 2 | Advanced Solid Tumor |
Price & technical context
3-month
-2.6%
6-month
+5.1%
12-month
-24.5%
52-wk range
$7.14–$11.90
vs 50-day MA
-1.5%
vs 200-day MA
+3.9%
Realized vol
44.2%
Max drawdown
-65.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for XLO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.